Indoleamine 2,3-Dioxygenase Activity Is Increased in Myelodysplastic Syndrome Patients

Kimihiro Yamaguchi; Soranobu Ninomiya; Takuro Matsumoto; Nobuhiko Nakamura; Hiroshi Nakamura; Junichi Kitagawa; Nobuhiro Kanemura; Takeshi Hara; Suwako Fujigaki; Yasuko Yamamoto; Kuniaki Saito; Hisashi Tsurumi; Masahito Shimizu

doi:10.3390/hemato1020011

Indoleamine 2,3-Dioxygenase Activity Is Increased in Myelodysplastic Syndrome Patients

Kimihiro Yamaguchi, Soranobu Ninomiya, Takuro Matsumoto, Nobuhiko Nakamura, Hiroshi Nakamura, Junichi Kitagawa, Nobuhiro Kanemura, Takeshi Hara, Suwako Fujigaki, Yasuko Yamamoto, Kuniaki Saito, Hisashi Tsurumi, Masahito Shimizu

Advanced Diagnostic System Development

Research output: Contribution to journal › Article › peer-review

Abstract

Tryptophan (TRP) metabolism via the indoleamine 2,3-dioxygenase (IDO) subset of the kynurenine (KYN) pathway is one of the most important mechanisms of immune escape in cancer. TRP is converted into several biologically active KYN metabolites. However, the role of KYN metabolic products and related enzymes has not been clarified in patients with hematological malignant tumors. Here, we examined the serum concentrations of TRP, KYN, and the KYN metabolites kynurenic acid, anthranilic acid, and 3-hydroxyanthranilic acid in 157 patients stratified into five different hematological malignant tumors. KYN was the most abundant product of the TRP metabolic pathway among all five diagnostic categories. Serum KYN was increased in myelodysplastic syndrome (MDS) patients. The KYN/TRP ratio was significantly higher in MDS patients than in acute myeloid leukemia patients. In conclusion, IDO activity is increased in MDS patients, and IDO inhibitors might represent a new therapeutic approach for MDS treatment.

Original language	English
Pages (from-to)	77-85
Number of pages	9
Journal	Hemato
Volume	1
Issue number	2
DOIs	https://doi.org/10.3390/hemato1020011
Publication status	Published - 12-2020

All Science Journal Classification (ASJC) codes

Hematology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/hemato1020011

Cite this

@article{68f94e046f9940749d1a7bf7df6ae1b6,

title = "Indoleamine 2,3-Dioxygenase Activity Is Increased in Myelodysplastic Syndrome Patients",

abstract = "Tryptophan (TRP) metabolism via the indoleamine 2,3-dioxygenase (IDO) subset of the kynurenine (KYN) pathway is one of the most important mechanisms of immune escape in cancer. TRP is converted into several biologically active KYN metabolites. However, the role of KYN metabolic products and related enzymes has not been clarified in patients with hematological malignant tumors. Here, we examined the serum concentrations of TRP, KYN, and the KYN metabolites kynurenic acid, anthranilic acid, and 3-hydroxyanthranilic acid in 157 patients stratified into five different hematological malignant tumors. KYN was the most abundant product of the TRP metabolic pathway among all five diagnostic categories. Serum KYN was increased in myelodysplastic syndrome (MDS) patients. The KYN/TRP ratio was significantly higher in MDS patients than in acute myeloid leukemia patients. In conclusion, IDO activity is increased in MDS patients, and IDO inhibitors might represent a new therapeutic approach for MDS treatment.",

author = "Kimihiro Yamaguchi and Soranobu Ninomiya and Takuro Matsumoto and Nobuhiko Nakamura and Hiroshi Nakamura and Junichi Kitagawa and Nobuhiro Kanemura and Takeshi Hara and Suwako Fujigaki and Yasuko Yamamoto and Kuniaki Saito and Hisashi Tsurumi and Masahito Shimizu",

note = "Publisher Copyright: {\textcopyright} 2020 by the authors.",

year = "2020",

month = dec,

doi = "10.3390/hemato1020011",

language = "English",

volume = "1",

pages = "77--85",

journal = "Hemato",

issn = "2673-6357",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "2",

}

TY - JOUR

T1 - Indoleamine 2,3-Dioxygenase Activity Is Increased in Myelodysplastic Syndrome Patients

AU - Yamaguchi, Kimihiro

AU - Ninomiya, Soranobu

AU - Matsumoto, Takuro

AU - Nakamura, Nobuhiko

AU - Nakamura, Hiroshi

AU - Kitagawa, Junichi

AU - Kanemura, Nobuhiro

AU - Hara, Takeshi

AU - Fujigaki, Suwako

AU - Yamamoto, Yasuko

AU - Saito, Kuniaki

AU - Tsurumi, Hisashi

AU - Shimizu, Masahito

PY - 2020/12

Y1 - 2020/12

N2 - Tryptophan (TRP) metabolism via the indoleamine 2,3-dioxygenase (IDO) subset of the kynurenine (KYN) pathway is one of the most important mechanisms of immune escape in cancer. TRP is converted into several biologically active KYN metabolites. However, the role of KYN metabolic products and related enzymes has not been clarified in patients with hematological malignant tumors. Here, we examined the serum concentrations of TRP, KYN, and the KYN metabolites kynurenic acid, anthranilic acid, and 3-hydroxyanthranilic acid in 157 patients stratified into five different hematological malignant tumors. KYN was the most abundant product of the TRP metabolic pathway among all five diagnostic categories. Serum KYN was increased in myelodysplastic syndrome (MDS) patients. The KYN/TRP ratio was significantly higher in MDS patients than in acute myeloid leukemia patients. In conclusion, IDO activity is increased in MDS patients, and IDO inhibitors might represent a new therapeutic approach for MDS treatment.

AB - Tryptophan (TRP) metabolism via the indoleamine 2,3-dioxygenase (IDO) subset of the kynurenine (KYN) pathway is one of the most important mechanisms of immune escape in cancer. TRP is converted into several biologically active KYN metabolites. However, the role of KYN metabolic products and related enzymes has not been clarified in patients with hematological malignant tumors. Here, we examined the serum concentrations of TRP, KYN, and the KYN metabolites kynurenic acid, anthranilic acid, and 3-hydroxyanthranilic acid in 157 patients stratified into five different hematological malignant tumors. KYN was the most abundant product of the TRP metabolic pathway among all five diagnostic categories. Serum KYN was increased in myelodysplastic syndrome (MDS) patients. The KYN/TRP ratio was significantly higher in MDS patients than in acute myeloid leukemia patients. In conclusion, IDO activity is increased in MDS patients, and IDO inhibitors might represent a new therapeutic approach for MDS treatment.

UR - http://www.scopus.com/inward/record.url?scp=85178020418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85178020418&partnerID=8YFLogxK

U2 - 10.3390/hemato1020011

DO - 10.3390/hemato1020011

M3 - Article

AN - SCOPUS:85178020418

SN - 2673-6357

VL - 1

SP - 77

EP - 85

JO - Hemato

JF - Hemato

IS - 2

ER -

Indoleamine 2,3-Dioxygenase Activity Is Increased in Myelodysplastic Syndrome Patients

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this